By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


InterMune, Inc. 

3280 Bayshore Boulevard

Brisbane  California  94005  U.S.A.
Phone: 415-466-2200 Fax: 415-466-2329

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a product portfolio addressing IPF and HCV infections. The pulmonology portfolio includes Actimmune®, which is being evaluated in the INSPIRE Trial, a Phase III study in patients with IPF, and pirfenidone, which is also being developed for the treatment of IPF. The hepatology portfolio includes the lead HCV protease inhibitor compound (ITMN B), a second-generation HCV protease inhibitor program, and a research program evaluating a new target in hepatology.

For additional information about InterMune and its R&D pipeline, please visit:

Key Statistics

Ownership: Public

Web Site: InterMune
Symbol: ITMN

Drug Discovery

Company News
Ex-InterMune (ITMN) Executive, Friend Found Liable For $1 Million Insider Trading Scheme 11/15/2016 7:36:07 AM
With Ex-InterMune (ITMN) Exec at Its Helm, AveXis Scores $65 Million 9/8/2015 4:46:05 PM
The Pink Slip Valentine: Companies Making Job Cuts: Sanofi (SAN.PA), InterMune (ITMN), Abbott (ABT), Syngenta AG (SYT), GlaxoSmithKline (GSK), Amgen (AMGN) 2/13/2015 4:22:58 AM
Consolidation Begins as 170 InterMune, Inc. (ITMN) Workers to be Eliminated By Mid-February 1/8/2015 3:15:01 PM
After $8.3 Billion Sale to Roche (RHHBY), InterMune, Inc. (ITMN) Chief Jumps to Venture Capital 1/8/2015 9:04:11 AM
InterMune, Inc. (ITMN) Wins FDA Approval For Lung Drug At Center Of Roche (RHHBY) Deal 10/15/2014 3:16:10 PM
Roche (RHHBY) Purchases Shares In Tender Offer For InterMune, Inc. (ITMN) 9/29/2014 8:45:53 AM
InterMune, Inc. (ITMN) Reports Memorandum Of Understanding In Connection With Consolidated Delaware Action 9/23/2014 7:39:53 AM
InterMune, Inc. (ITMN) Announces Anticipated Fundamental Change For 5.00% Convertible Senior Notes Due 2015 9/5/2014 12:52:44 PM
InterMune, Inc. (ITMN) CEO: Bittersweet Ending To A Biotech Comeback Story 8/26/2014 6:33:46 AM